Immedica wins accelerated approval for once-rejected rare disease drugnews2026-02-24T14:18:23+00:00February 24th, 2026|Endpoints News|
New biotech Slate Medicines raises $130M for migraine drug from Chinanews2026-02-24T12:30:21+00:00February 24th, 2026|Endpoints News|
AI biotech Turbine raises $25M Series B to sell ‘Virtual Lab’ to pharmanews2026-02-24T12:00:54+00:00February 24th, 2026|Endpoints News|
Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to marketnews2026-02-24T11:37:17+00:00February 24th, 2026|Endpoints News|
Pfizer buys China rights to Sciwind’s approved GLP-1 drug in metabolic pushnews2026-02-24T08:30:05+00:00February 24th, 2026|Endpoints News|
Hims reports 2025 earnings, shares details on GLP-1 pill decisionsnews2026-02-24T08:00:50+00:00February 24th, 2026|Endpoints News|
Astellas pays $240M cash for Vir’s prostate cancer drugnews2026-02-23T22:02:27+00:00February 23rd, 2026|Endpoints News|
QurAlis’ ALS drug sees early positive signal, but questions remainnews2026-02-23T20:44:51+00:00February 23rd, 2026|Endpoints News|
Swiss Rockets buys MGI subsidiary Complete Genomics after Biosecure Actnews2026-02-23T19:56:05+00:00February 23rd, 2026|Endpoints News|
Fortress to sell priority review voucher for $205Mnews2026-02-23T19:34:21+00:00February 23rd, 2026|Endpoints News|
